On July 4, shares of Zhongshan-based company Akeso rose for two consecutive days in the Hong Kong stock market, propelling its market value to exceed HK$100 billion for the first time.

As the world's sole pharmaceutical company with two novel tumor immunotherapy bispecific antibodies approved, Akeso has developed a robust pipeline of over 50 innovative drug candidates targeting major diseases including cancer, autoimmune disorders, inflammation, and metabolic diseases.